Navigation Links
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Date:2/13/2008

change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development (including the successful development of JUVISTA(R) (Human TGFb3)), manufacturing and commercialization (including the launch and establishment in the market of VYVANSE(TM)); the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine) extended release (ADHD) and GA-GCB (Gene-Activated Glucocerebrosidane); Shire's ability to secure new products for commercialization and/or development; Shire's ability to benefit from its acquisition of New River Pharmaceuticals Inc.; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.

---------------------------------

(1) Epsicom Business Intelligence. (June 30, 2007) The Pharmaceutical Market: Mexico


'/>"/>
SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Genzyme Receives Approval to Market Elaprase(R) in Japan
3. Clexane(R)/Lovenox(R) Approved in Japan
4. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
5. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
6. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
7. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Biomoda Announces Collaborative Agreement With New Mexico Tech
10. Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean
11. Prestigious Bioethics Award for Scholar from Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Cereal grain scientists, ... will gather October 5–8, 2014, for the AACC ... Convention Center in Providence, Rhode Island. The comprehensive ... of food scientists, chemists, microbiologists, nutritionists, and those ... production management. To date, 1,000 attendees have registered ...
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... 18, 2014 ... ) has announced the addition of ... Strategic Business Report" report to ... report analyzes the worldwide markets for ... the following Product Segments: Polymeric Materials, ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Albumin Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... The report provides a basic overview of the ... The human albumin market analysis is provided for the ...
Breaking Biology Technology:Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3
... Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the ... treated in a Phase 1b clinical trial of ... a proprietary small molecule,inhibitor of thioredoxin, a protein ... growth, survival and drug resistance of,many cancers., ...
... to Healthcare Organizations through CSC,s ... ... CSC (NYSE: CSC ) today,announced that its enterprise ... FirstPortfolio offering.,FirstPoint streamlines a health organization,s document management,processes and incorporates ...
... (OTC BB BSTC.OB-News) today announced that it sold ... stock priced at $15,per share for aggregate proceeds ... certain private investors on June 9, 2008. The ... at a premium over the,market price., BioSpecifics ...
Cached Biology Technology:Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3CSC Adds Content Management to Hosted Healthcare Offering 2
(Date:9/21/2014)... years, new strains of bacteria have emerged that resist ... including drug-resistant forms of tuberculosis and staphylococcus, infect more ... 23,000. Despite the urgent need for new treatments, scientists ... the past decade. , MIT engineers have now turned ... gene-editing system that can disable any target gene, they ...
(Date:9/21/2014)... a protein therapy that disrupts the process that causes ... travel through the blood stream and start aggressive new ... as metastasis, can cause cancer to spread with deadly ... to cancer fall prey to metastatic forms of the ... who describes a new therapeutic approach in Nature ...
(Date:9/19/2014)... professor will study the unique bioelectric signaling system of ... people,s health. The OU researcher is working to ... produce the signals used to map the world around ... rate of 500-600 discharges a second throughout their lives. ... are extreme, but necessary for survival. , "There is ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... imaging technique to track the effects of next-generation nanomedicines ... Strathclyde academic. Professor Dr. M. N. V. Ravi ... of Pharmacy and Biomedical Sciences, believe an advanced form ... boost developments in the field of nanomedicines, the encapsulation ...
... the collaboration between Janssen, J&J Innovation, VIB, KU Leuven ... in translating basic molecular insights to diagnostics and therapeutics ... are committing up to 5 million Euros for this ... research projects from VIB, KU Leuven and UZ Leuven. ...
... obesity, endocrine-disrupting chemicals, adolescent health and clinical trials will be ... The 95th Annual Meeting & Expo of The Endocrine Society. ... 15 Adolescent Health (10 a.m. PDT): New insights ... conditions including eating disorders and gender identity disorder. ...
Cached Biology News:Nanomedicines' impact on patients under the microscope 2Nanomedicines' impact on patients under the microscope 3Janssen, J&J Innovation, VIB, KU Leuven and UZ Leuven join forces to combat neurological diseases 2
Plasmid expressing the LacZ reporter gene....
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... 2800mL PYREX Fernbach-style culture flasks have triple ... flask bottom to achieve maximal oxygen transfer ... large marking spot., A wide range of ... including:, Polypropylene colored caps for ease ...
... of purified RNA samples., , This product ... aqueous RNA samples that have been pre-purified ... silica, oligo dT etc or other kits. ... necessary components for the stabilization of nanogram ...
Biology Products: